Showing 1 - 10 of 71
In recent years data-sharing has been a recurring focus of struggle within the scientific research community as improvements in information technology and digital networks have expanded the ways that data can be produced, disseminated, and used. Information technology makes it easier to share...
Persistent link: https://www.econbiz.de/10009471554
Recent Supreme Court cases on patent-eligible subject matter are likely to exacerbate the longstanding problem of biomedical data fragmentation. For each data silo, multiple overlapping legal claims and claimants must be addressed to achieve the benefits of pooling.Commentators who have...
Persistent link: https://www.econbiz.de/10012959520
As scholars who write in intellectual property (“IP”), we write this letter with aspirations of reaching the highest ethical norms possible for our field. In particular, we have noted an influx of large contributions from corporate and private actors who have an economic stake in ongoing...
Persistent link: https://www.econbiz.de/10012855788
Pharmaceutical firms may forego development of small molecules for which they cannot secure strong “product” or “composition-of-matter” patents. During the time these composition-of-matter patents remain in force, they not only block third parties from marketing the drug for the...
Persistent link: https://www.econbiz.de/10013049497
This contribution to the Research Handbook on Economics of Intellectual Property Rights (Vol. 1 Theory) addresses interactions between the principal legal institutions of the U.S. patent system. It considers legal, strategic, and normative perspectives on these interactions as they have evolved...
Persistent link: https://www.econbiz.de/10012991946
The America Invents Act of 2011 (“AIA”) created a robust administrative system—the Patent Trial and Appeal Board (“PTAB”)—for challenging the validity of granted patents. Congress determined that administrative correction of errors made in initial patent grants could be cheaper and...
Persistent link: https://www.econbiz.de/10013217065
As finding breakthrough small-molecule drugs gets harder, drug companies are increasingly turning to “large molecule” biologics. Although biologics represent many of the most promising new therapies for previously intractable diseases, they are extremely expensive. Moreover, the pathway for...
Persistent link: https://www.econbiz.de/10013219143
In this comment to ITC Investigation 337-TA-745 (Certain Wireless Communication Devices, Motorola v. Apple) we, as teachers and scholars of economics, antitrust and intellectual property, remedies, administrative, and international intellectual property law, former Department of Justice lawyers...
Persistent link: https://www.econbiz.de/10013036745
The available evidence indicates that patent quality, particularly in the area of software, needs improvement. This Article, to be published in a Symposium on intellectual property and information law in the administrative state, argues that even an agency as institutionally constrained as the...
Persistent link: https://www.econbiz.de/10013062023
In recent years, widespread dissatisfaction with the perceived poor quality of issued patents has spurred a diverse range of groups to call for reform of administrative procedures. Strikingly, however, most calls for reform pay little attention to principles of administrative law. Similarly,...
Persistent link: https://www.econbiz.de/10012748153